Apyx Medical to Showcase Turnaround at Key Investor Conference

CLEARWATER, FL – January 29, 2026 – Apyx Medical Corporation is set to engage with the investment community at a pivotal moment, as management prepares to participate in the prestigious BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10 in Snowbird, Utah. The appearance comes as the surgical aesthetics company (NASDAQ:APYX) rides a wave of positive financial momentum and the strategic launch of its new flagship platform, the AYON Body Contouring System.

For a company that has navigated years of financial challenges, this conference represents more than a routine update. It is a critical opportunity to present a compelling turnaround narrative to institutional investors, backed by strengthening revenues, favorable analyst outlooks, and technological innovation aimed squarely at the fastest-growing segments of the aesthetics market.

A Story of Financial Revival

After 13 consecutive years of reported losses, Apyx Medical is beginning to script a new chapter focused on growth and a clear path toward profitability. The company’s most recent financial disclosures paint a picture of significant operational improvement. In its Third Quarter 2025 earnings report, Apyx surpassed analyst expectations with an EPS of -$0.05 against a forecast of -$0.10, and revenue of $12.9 million that beat estimates of $12 million. This performance was fueled by a robust 19% year-over-year increase in its core Surgical Aesthetics segment.

More impressively, the company announced preliminary unaudited revenue results for the fourth quarter and full year of 2025 that suggest this momentum is accelerating. Total revenue for Q4 2025 is projected to land between $19.0 and $19.2 million, a staggering 34% increase compared to the prior year. The Surgical Aesthetics division is expected to grow by an even more impressive 38% year-over-year. This strong finish prompted the company to raise its full-year 2025 revenue guidance, a move largely attributed to strong initial demand for its newly launched AYON system.

This financial upswing has not gone unnoticed. While Apyx’s stock has seen volatility, it surged nearly 18% in the month following its strong Q3 report. The broader analyst community holds a “Moderate Buy” consensus rating on the stock, with an average twelve-month price target of $7.00—a significant upside from its current trading range. Three out of five brokerage firms covering the company rate it a “Strong Buy.” This optimism provides a powerful tailwind as management prepares to meet with investors who will be keen to understand if this growth is sustainable.

Technology Reshaping the Contouring Landscape

At the heart of Apyx Medical’s resurgence is its proprietary Helium Plasma Platform Technology. Marketed as Renuvion, the technology delivers a unique combination of radiofrequency (RF) energy and helium plasma to provide controlled heat to tissue. This process causes collagen fibers to contract, resulting in significant skin tightening—a crucial component of modern body contouring procedures.

The company’s regulatory journey with Renuvion highlights both its challenges and its perseverance. In March 2022, the FDA issued a safety communication cautioning against certain “off-label” aesthetic uses of the device. However, Apyx responded by securing a series of specific FDA 510(k) clearances. These include clearances for treating wrinkles and rhytides, improving the appearance of loose skin in the neck and submental region, and, most critically, for use following liposuction to address soft tissue coagulation. This last clearance, granted in May 2023, made Renuvion the only device on the market specifically cleared for this post-liposuction application, cementing its place in the surgical workflow.

Building on this foundation, Apyx launched the AYON Body Contouring System in mid-2025. This FDA-cleared, all-in-one platform is designed to be the centerpiece of the aesthetic surgical suite. It seamlessly integrates ultrasound-assisted liposuction for fat removal, electrosurgical capabilities, and the signature Renuvion technology for tissue contraction. The integrated system streamlines procedures, empowering surgeons to deliver more comprehensive treatments on a single device. Further enhancing its utility, Apyx submitted another 510(k) in late 2025 to add power liposuction capabilities, which, if cleared, would solidify AYON as the first truly comprehensive and fully integrated body contouring platform available.

Capitalizing on a Booming Aesthetics Market

Apyx Medical’s strategic focus and technological advancements are perfectly timed to capitalize on powerful trends driving the global aesthetics industry. The body contouring market alone was valued at nearly $2 billion in 2025 and is projected to exceed $6.6 billion by 2034, growing at a compound annual growth rate of over 14%. A major catalyst for this growth is the increasing demand for minimally invasive procedures that offer effective results with less downtime.

Furthermore, the widespread use of GLP-1 therapies for weight loss has created an entirely new and rapidly growing patient demographic. Individuals who achieve significant weight loss are often left with loose, lax skin, creating a surge in demand for effective skin-tightening solutions. Renuvion and the AYON system are directly positioned to meet this need, offering a less invasive alternative to more extensive surgical excisions like a tummy tuck. This market opportunity is a key part of the company's growth narrative.

The competitive landscape is fierce, with major players like InMode offering rival RF-based technologies. However, Apyx has carved out a strong reputation among practitioners. In a recent independent survey, Renuvion was named the #1 trusted body contouring technology by doctors, with a significant majority of surgeons preferring its use after liposuction to achieve superior results.

The BTIG Stage: Opportunity and Scrutiny

Participation in the BTIG conference provides Apyx Medical a direct channel to a sophisticated investor audience. The event is known for connecting innovative companies with capital decision-makers and is hosted by analysts with deep sector expertise. Interestingly, BTIG itself initiated coverage of Apyx with a more cautious “Neutral” or “Hold” rating in 2024 and 2025, even as other firms grew more bullish. This context makes the upcoming meetings particularly significant, as Apyx management will have the opportunity to directly address any lingering skepticism and make their case for the company's re-evaluation.

The key message will undoubtedly center on the successful commercial launch of the AYON system as a primary growth driver, the clear and accelerating trend toward profitability, and the company’s strategic position to dominate the burgeoning market for post-weight loss skin contraction. For investors, the conference will be a chance to scrutinize the company’s strategy and determine whether its recent financial performance marks the beginning of a sustained, long-term growth trajectory. How effectively Apyx communicates this vision could have a lasting impact on its market perception and valuation moving forward.